PMC:7309518 / 303-636 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":237,"end":245},"obj":"Body_part"},{"id":"T2","span":{"begin":251,"end":256},"obj":"Body_part"},{"id":"T3","span":{"begin":257,"end":268},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma65132"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma82780"}],"text":"immunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myo"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":251,"end":256},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001021"}],"text":"immunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myo"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T10","span":{"begin":94,"end":97},"obj":"Disease"},{"id":"T11","span":{"begin":116,"end":124},"obj":"Disease"},{"id":"T12","span":{"begin":288,"end":296},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"immunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myo"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":251,"end":256},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"}],"text":"immunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myo"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":237,"end":245},"obj":"Chemical"},{"id":"T2","span":{"begin":257,"end":268},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_33563"}],"text":"immunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myo"}

{"project":"LitCovid-PubTator","denotations":[{"id":"15","span":{"begin":116,"end":124},"obj":"Disease"},{"id":"16","span":{"begin":225,"end":230},"obj":"Disease"},{"id":"17","span":{"begin":288,"end":296},"obj":"Disease"}],"attributes":[{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"MESH:C000657245"},{"id":"A16","pred":"tao:has_database_id","subj":"16","obj":"MESH:C000657245"},{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"immunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myo"}

{"project":"LitCovid-sentences","denotations":[{"id":"T7","span":{"begin":79,"end":86},"obj":"Sentence"},{"id":"T8","span":{"begin":87,"end":269},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"immunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myo"}